Please login to the form below

Not currently logged in
Email:
Password:

Pfizer generic on hold until 2019

A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019
A US district court has ruled against Teva Pharmaceuticals marketing a generic version of Viagra until its Pfizer patent expires in October 2019.

Israel-based Teva had claimed Pfizer's patent on Viagra (sildenafil) wasn't valid and couldn't be enforced. It also claimed that Pfizer intentionally withheld documents from the US Patent and Trademark Office.

But US Judge Rebecca Smith, Virginia said that Teva had presented no clear and convincing evidence to support this, in a 110-page opinion.

The decision was made at the end of a two-week non-jury trial. It protects Pfizer's $1bn a year in US Viagra sales.

Pfizer has noted that the decision is subject to appeal. Litigation on the same patent against other companies remains pending.

16th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics